Can SSRIs Cause Tardive Dyskinesia?

SSRIs can cause tardive dyskinesia, but the occurrence is rare enough that some researchers have questioned whether the link is real or an artifact of prior antipsychotic use. Case reports exist across several SSRIs, and pharmacovigilance databases contain hundreds of reports, yet the overall risk remains far lower than with the dopamine-blocking drugs traditionally blamed for tardive dyskinesia. The question is more nuanced than a simple yes or no, and understanding it means untangling confounding medication histories, serotonin-dopamine crosstalk, and individual differences in how people metabolize these drugs.

What the Case Reports Actually Show

Tardive dyskinesia involves involuntary, repetitive movements, often of the face, tongue, and jaw, that develop after prolonged use of certain medications and can persist even after the drug is stopped. It has been most strongly associated with older antipsychotics, but scattered case reports have tied it to SSRIs as well. One published case described a patient who developed both tardive dyskinesia and akathisia while taking citalopram.¹ Another involved a 49-year-old woman who developed involuntary facial movements after just three months on sertraline at a standard dose, with no history of antipsychotic use or any other medication that could explain the movements.²

A broader review of published literature identified six cases of tardive dyskinesia specifically attributed to SSRIs in the medical literature, along with 76 cases reported directly to SSRI manufacturers.³ Those manufacturer reports also included hundreds of cases of other movement problems: parkinsonism, dyskinesia, dystonia, and akathisia. The numbers sound alarming until you consider the millions of people taking SSRIs at any given time. Still, the reports are not nothing. They establish that the association exists, even if it is uncommon.

The Antipsychotic Confound

Here is where the picture gets muddied. Many people prescribed SSRIs for depression or anxiety also take or have previously taken antipsychotic medications, which are the drugs most strongly linked to tardive dyskinesia. When someone develops involuntary movements while on an SSRI, it can be genuinely difficult to determine whether the SSRI triggered the problem or whether prior antipsychotic exposure planted the seed. A review of movement disorders caused by psychiatric drugs that do not block dopamine receptors concluded that SSRI-induced tardive dyskinesia “almost never occurs without prior or concurrent neuroleptic exposure.”⁴

That “almost never” is important. It does not mean “never.” The sertraline case described above involved a patient with no antipsychotic history at all.² Cases like that are the strongest evidence that SSRIs can independently cause tardive dyskinesia, precisely because the usual alternative explanation does not apply. But they are the exception rather than the rule, and clinicians who see movement problems in SSRI patients will typically look first at whether antipsychotics were involved at some point in the patient’s medication history.

How Serotonin Could Disrupt Movement

Tardive dyskinesia has traditionally been understood as a consequence of blocking dopamine receptors in the brain’s motor circuits. Antipsychotics do this directly, which is why they carry a well-known risk. SSRIs do not block dopamine receptors. They increase serotonin levels. So how could they cause a dopamine-related movement disorder?

The connection runs through the crosstalk between serotonin and dopamine systems. Serotonin neurons project into brain regions involved in movement control, and their activity influences how much dopamine gets released there. Research in animals has shown that activating certain serotonin receptors in the striatum, a key movement-control region, decreases dopamine release.⁵ In other words, flooding the brain with extra serotonin could, under certain conditions, indirectly alter dopamine signaling in ways that affect movement.

The relationship is not straightforward, though. Other research found that serotonin does not significantly affect dopamine release under resting conditions in the striatum. The influence kicks in when the dopamine system is already active.⁶ This suggests that the serotonin-dopamine interaction depends on context, and that individual variation in baseline dopamine function could determine who is vulnerable. It may help explain why most people take SSRIs without developing movement problems, while a small number do.

Which SSRIs Are Most Linked to Movement Problems

Not all SSRIs carry the same level of signal in pharmacovigilance databases. A large postmarketing study that analyzed VigiBase, the World Health Organization’s global database of adverse drug reactions, found that among the millions of reports in the system, about 7% involved an antidepressant. Of those antidepressant-related reports, roughly 3% mentioned movement disorders. When the researchers looked at which specific drugs were most frequently associated with movement disorders, citalopram and paroxetine stood out among the SSRIs, while fluvoxamine showed one of the strongest associations when comparing reporting rates relative to other antidepressants.⁷

The same study found that serotonin reuptake inhibitors as a class were significantly associated with all subtypes of movement disorders except restless legs syndrome. The strongest association was with bruxism, or involuntary teeth grinding, which had a reporting odds ratio above ten, meaning it was reported far more often with antidepressants than with other drugs in the database. Tardive dyskinesia and other dyskinesias were also flagged, though the association was weaker than for bruxism.

These pharmacovigilance numbers come with an important caveat. Reporting databases capture signals, not causation. A drug being frequently reported alongside an adverse event does not prove it caused the event, especially when patients are often on multiple medications. But the data do suggest that movement-related side effects are not exclusive to any single SSRI and that prescribers should be aware of the possibility across the class.

Who Faces Higher Risk

When researchers looked at patients who developed movement disorders on SSRIs, certain patterns emerged. People who developed dystonia, parkinsonism, or tardive dyskinesia on SSRIs tended to be older than those who developed akathisia, and about two-thirds were women.⁸ This mirrors what is known about tardive dyskinesia from antipsychotic use, where older age and female sex are established risk factors.

Beyond demographics, concurrent or past use of neuroleptics, existing neurological conditions, and pre-existing movement disorders have all been identified as factors that may make someone more susceptible.³ If your brain’s dopamine system is already compromised, whether from a neurological condition or from prior drug exposure, the indirect dopamine effects of an SSRI could be enough to tip the balance. This is part of why the condition is so rare in the general SSRI-taking population but crops up in people with more complicated medical and medication histories.

The bottom line for risk: a young, otherwise healthy person starting an SSRI for the first time with no history of antipsychotic use faces an extremely low risk of tardive dyskinesia. An older woman with a history of antipsychotic treatment and a pre-existing neurological condition is in a different position entirely.

Drug Metabolism and Genetic Vulnerability

How your body processes an SSRI matters. Most SSRIs are broken down in the liver by an enzyme called CYP2D6, and people differ dramatically in how active that enzyme is. Some people are “poor metabolizers” whose CYP2D6 barely functions, meaning the drug lingers in the body at higher concentrations for longer. Others are “ultra-rapid metabolizers” who clear the drug quickly.

One study of patients who developed movement-related side effects from psychiatric drugs found that poor metabolizers were heavily over-represented. Among patients with the most severe movement side effects, nearly half were poor metabolizers, far more than you would expect in the general population, where the rate is typically under 10% in most ethnic groups. The patients who did not develop movement problems had significantly more functional copies of the gene.⁹

A smaller pilot study that specifically tested CYP2D6 status in psychiatric patients found no statistically significant association overall between metabolizer status and side effects across the full sample, but individual cases of poor and ultra-rapid metabolizers showed noticeable problems with either side effects or lack of drug response.¹⁰ The finding suggests that while genetic testing may not predict risk well across broad populations, it could be clinically meaningful for individuals at the metabolic extremes.

Pharmacogenomic testing for CYP2D6 is now available and increasingly used in psychiatry, though its adoption is far from universal. If you are concerned about movement side effects and have a family history of unusual drug reactions, asking your prescriber about CYP2D6 testing is a reasonable step.

Do SSRIs Make Antipsychotic-Induced Tardive Dyskinesia Worse?

A related concern is whether adding an SSRI to an existing antipsychotic regimen increases the risk of developing movement side effects. Since SSRIs affect serotonin, which in turn modulates dopamine, it is plausible that combining the two classes could amplify the problem. This question has been studied directly, and the results are somewhat reassuring. A comparison of patients on antipsychotics alone, antipsychotics plus one SSRI, and antipsychotics plus two SSRIs found no significant differences in the rates of movement side effects among the three groups.¹¹

That result is based on limited data, and the relative risk of movement problems from SSRIs in general has yet to be firmly established.¹² But it does suggest that for most patients already taking an antipsychotic, the addition of an SSRI does not markedly worsen the picture. This matters clinically because depression is common in people with schizophrenia and other conditions treated with antipsychotics, and withholding effective antidepressant treatment based on a theoretical risk that has not materialized in studies would be harmful in its own right.

The Fluvoxamine Paradox

In a strange twist, one SSRI has been studied not as a cause of tardive dyskinesia but as a potential treatment for it. Fluvoxamine, in addition to being an SSRI, acts on sigma-1 receptors in the brain, which are involved in neuroprotection and cellular stress responses. In an animal study, rats given haloperidol to induce tardive dyskinesia showed improvement in symptoms when treated with fluvoxamine. The researchers attributed the benefit to fluvoxamine’s sigma-1 activity rather than its serotonin effects and found improvements in both behavioral symptoms and biochemical markers of oxidative stress.⁷

This creates a paradox where the same drug class occasionally associated with causing tardive dyskinesia may also contain a member that can treat it. The distinction likely lies in mechanism: fluvoxamine’s sigma-1 activity is pharmacologically separate from its serotonin reuptake inhibition. The animal data is preliminary and has not been validated in human clinical trials for this purpose, but it highlights just how tangled the relationship between serotonin drugs and movement disorders really is.

Quality of Life and What to Watch For

When drug-induced dyskinesia does occur with SSRIs, it can significantly affect quality of life and complicate treatment of the underlying psychiatric condition.¹³ Involuntary facial movements are not only physically uncomfortable but can be socially distressing, leading some patients to stop their antidepressant without guidance, which carries its own risks including withdrawal symptoms and relapse of the condition being treated.

If you are taking an SSRI and notice new involuntary movements, particularly of the tongue, jaw, or lips, the first step is to contact your prescriber rather than abruptly stopping the medication. Early recognition matters because tardive dyskinesia is defined by its tendency to persist even after the offending drug is discontinued. The earlier the abnormal movements are caught and the medication is adjusted, the better the chances that the movements will resolve. Your prescriber may switch you to a different antidepressant, adjust the dose, or add a treatment specifically for dyskinesia.

Movements that appear within the first few days of starting or increasing an SSRI are more likely to be acute dystonia or akathisia rather than tardive dyskinesia, which by definition develops after prolonged exposure, typically months or longer. The distinction is clinically important because acute reactions tend to resolve quickly once the drug is adjusted, while true tardive dyskinesia can be much more persistent.

SSRIs and Parkinson’s Disease

An interesting related question is whether SSRIs are safe for people with Parkinson’s disease, a condition in which the dopamine system is already degenerating. Depression is extremely common in Parkinson’s patients, and SSRIs are among the most commonly prescribed treatments for it. The concern is that anything that further alters dopamine signaling, even indirectly through serotonin, could worsen motor symptoms. Early reviews of the evidence noted that the rare occurrence of movement side effects in patients receiving SSRIs should not prevent their use in Parkinson’s disease, where their role in treating depression needs more systematic study.¹²

In practice, SSRIs are widely used in Parkinson’s patients, and clinicians generally monitor for motor changes when starting or adjusting these medications. The risk-benefit calculation typically favors treatment, since untreated depression in Parkinson’s disease worsens disability, cognitive decline, and overall prognosis. But the theoretical vulnerability of an already-compromised dopamine system remains a reason for closer monitoring in this population compared to the general antidepressant-taking public.

Bruxism and Other Movement Effects That Get Overlooked

While tardive dyskinesia gets attention because of its severity and persistence, other movement-related side effects of SSRIs are more common and often go unrecognized. Bruxism, or involuntary clenching and grinding of the teeth, was the movement disorder with the strongest pharmacovigilance signal for antidepressants in the WHO database, with a reporting odds ratio above ten.⁷ Many people experience jaw tightness or teeth grinding on SSRIs and attribute it to stress rather than their medication, meaning the true incidence is likely underreported.

Akathisia, a deeply uncomfortable inner restlessness and compulsion to move, is another SSRI-related movement effect that can be misdiagnosed as worsening anxiety. Dystonia, which involves sustained muscle contractions leading to abnormal postures, and drug-induced parkinsonism, with stiffness and slowed movement, also appear in case reports. The published literature on SSRI-induced movement disorders identified akathisia, dystonia, and parkinsonism alongside tardive dyskinesia, suggesting these effects exist on a shared spectrum rather than as isolated phenomena.³ If you develop any new movement symptoms while on an SSRI, including those that seem minor like jaw clenching, mentioning them to your prescriber gives them information that could matter for your ongoing care.